Drug Trial Radar · NCT07447102
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Apr 1, 2029
Study completion Apr 1, 2029
Sponsor
- Lead sponsor
- Dragonboat Biopharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BC006Drug
A 1.0 mg/kg or 0.3 mg/kg IV infusion of BC006 based on the patients weight will be administered Q2W to Week 24.
PlaceboDrug
lacebo matching BC006 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI), as well as vital signs, physical examination, 12-lead ECG, and laboratory tests, etc.Time frame: From Baseline up to Week 24
- Absolute change in FVC (mL) from baseline in week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dragonboat Biopharmaceutical,Co.,Ltd
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.